Last $8.97 USD
Change Today +0.01 / 0.11%
Volume 11.8K
IRIX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IRIX) Key Developments

IRIDEX Corporation Reports Unaudited Financial Results for the Fourth Quarter and Year Ended December 28, 2013; Provides Earnings Guidance for the First Quarter of 2014

IRIDEX Corporation reported unaudited financial results for the fourth quarter and year ended December 28, 2013. Revenues were $10.6 million in the fourth quarter of 2013, up 15% from $9.2 million in the prior year comparable period and up sequentially from $9.5 million in the third quarter of 2013. Operating income was $0.6 million compared with an operating income of $0.3 million for the fourth quarter of 2012. Net income from continuing operations was $0.4 million, or $0.04 per diluted share, for the fourth quarter of 2013, compared to a net income from continuing operations of $0.3 million, or $0.03 per diluted share, in the fourth quarter of 2012. Income from continuing operations before provision for income taxes was $385,000, compared to $287,000 for the last year. Net income was $412,000 or $0.04 per diluted share, compared to $242,000 or $0.02 per diluted share for the last year. Revenues for 2013 were $38.3 million, up 13% from $33.9 million in 2012. Operating income for 2013 was $2.6 million, up $3.5 million from an operating loss of $0.9 million in 2012. Net income from continuing operations for 2013 was $2.2 million compared to a loss from continuing operations of $0.2 million for 2012, or earnings of $0.22 per diluted share compared to a loss of $0.02 per share on a diluted basis. Income from continuing operations before provision for income taxes was $2,262,000, compared to loss of $270,000 for the last year. Net income was $2,231,000 or $0.22 per diluted share, compared to $1,438,000 or $0.16 per diluted share for the last year. For first quarter of 2014, the company expects to achieve revenue between $9.8 million and $10.1 million, representing growth of between 9% and 13% over the prior year period. Gross margin is anticipated to come in between 48% and 50%, operating expenses between $4.3 million and $4.5 million, and the company anticipates generating operating income.

IRIDEX Corporation, Q4 2013 Earnings Call, Feb 27, 2014

IRIDEX Corporation, Q4 2013 Earnings Call, Feb 27, 2014

IRIDEX Corporation to Report Q4, 2013 Results on Feb 27, 2014

IRIDEX Corporation announced that they will report Q4, 2013 results at 5:00 PM, Eastern Standard Time on Feb 27, 2014

IRIDEX Corporation Reports Preliminary Revenue Results for the Fourth Quarter and Full Year of 2103; Provides Gross Margin Guidance for the Fourth Quarter of 2103

IRIDEX Corporation reported preliminary revenue results for the fourth quarter and full year of 2103. For the quarter, revenues were approximately $10.6 million, driven by a continued strong uptick in sales of laser systems both in the U.S. and internationally. For the year, revenues were $38.3 million. The company anticipates gross margins for the 2013 fourth quarter just slightly below the guidance of between 49% and 51%.

IRIDEX Corporation to Introduce Four New Products at Annual American Academy of Ophthalmology Meeting

IRIDEX Corporation announced that it would introduce four new products at the annual meeting of the American Academy of Ophthalmology to be held November 16 to 19 at the Ernest N. Morial Convention Center in New Orleans. The products include: A new version of the TxCell(TM) Pattern Scanning Laser Delivery System. The new iteration of the high-speed delivery device is compatible with the large market of physician-owned slit lamps; A new IRIDEX MicroPulse Laser Trabeculoplasty (MLT) lens manufactured by Ocular Instruments. The new product, distributed exclusively through IRIDEX, is designed to increase efficiency and precision of MLT for the treatment of glaucoma; A portfolio of single-use 27-gauge laser probes, Peregrine Surgical-branded, that are compatible with the growing number of 27-gauge vitrectomy systems used in retina surgery; A GreenTip(TM) Membrane Scraper, available in 23 & 25 gauges, offering a single-use surgical device intended for specialized retinal surgery. The new device is designed to maximize visualization against the retina and is a derivative of the proprietary GreenTip product family.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRIX:US $8.97 USD +0.01

IRIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anika Therapeutics Inc $39.23 USD -0.10
Cutera Inc $10.79 USD -0.22
Ellex Medical Lasers Ltd A$0.34 AUD 0.00
Lutronic Corp 17,300 KRW +100.00
Synergetics USA Inc $3.31 USD -0.06
View Industry Companies
 

Industry Analysis

IRIX

Industry Average

Valuation IRIX Industry Range
Price/Earnings 40.6x
Price/Sales 2.3x
Price/Book 3.4x
Price/Cash Flow 40.2x
TEV/Sales 2.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.